Melevodopa
Appearance
Clinical data | |
---|---|
Trade names | Levomet |
Other names | Levodopa methyl ester; L-DOPA methyl ester; LDME; CHF-1301 |
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C10H13NO4 |
Molar mass | 211.217 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Melevodopa, also known as levodopa methyl ester (LDME) and sold under the brand name Levomet, is a dopaminergic agent. It is the methyl ester of levodopa.[1] It is used in oral tablet form as an effervescent prodrug with 250 times the water solubility of tablet levodopa.[2][3] In combination with carbidopa, as melevodopa/carbidopa (brand name Sirio), it is approved for use in the treatment of Parkinson's disease.[4][5]
See also
[edit]References
[edit]- ^ Buckingham J, Baggaley K, Roberts A, Szabo L (2010). Dictionary of Alkaloids with CD-ROM. CRC Press. p. 103. ISBN 978-1-4200-7770-4. Retrieved 28 September 2024.
- ^ Hickey P, Stacy M (2011). "Available and emerging treatments for Parkinson's disease: a review". Drug Design, Development and Therapy. 5: 241–254. doi:10.2147/DDDT.S11836. PMC 3096539. PMID 21607020.
- ^ Stocchi F, Marconi S (July 2010). "Factors associated with motor fluctuations and dyskinesia in Parkinson Disease: potential role of a new melevodopa plus carbidopa formulation (Sirio)". Clin Neuropharmacol. 33 (4): 198–203. doi:10.1097/WNF.0b013e3181de8924. PMID 20414107.
- ^ "Melevodopa/carbidopa". AdisInsight. Springer Nature Switzerland AG. 23 September 2021. Retrieved 27 September 2024.
- ^ "Melevodopa: Uses, Interactions, Mechanism of Action". DrugBank Online. 1 April 2015. Retrieved 27 September 2024.